MiniMed reports record $3.1B revenue, FDA clears two new products, guides 10% FY27 growth

Filed June 3, 2026 · Period ending June 3, 2026 · ~1 min read

Key Changes

• high

  Full-year revenue hit record $3.1B (up 14.2% reported, 8.0% organic), first time crossing $3B milestone; international sales drove growth at 20.6% reported.

  Exhibit 99.1 verify on EDGAR →
• high

  FDA cleared MiniMed Flex insulin pump and MiniMed Go Smart MDI system; Flex pre-orders started this week with shipping later this month, Go launched last week.

  Exhibit 99.1 verify on EDGAR →
• high

  FY2027 guidance: ~10% organic revenue growth (includes 1.0-1.5% benefit from extra week) and ~16% adjusted EBITDA margin.

  Exhibit 99.1 verify on EDGAR →